Literature DB >> 31682643

A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health.

Ahmad Moolla1,2, Kenzo Motohashi1, Thomas Marjot1,3, Amelia Shard3, Mark Ainsworth3, Alastair Gray4, Rury Holman2,5, Michael Pavlides2,3, John D Ryan2,3, Jeremy W Tomlinson1,2, Jeremy F Cobbold2,3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a globally prevalent health problem, associated in its more severe forms with increased liver-related and cardiovascular-related morbidity and mortality. We established a multidisciplinary metabolic hepatology clinic in 2014 and have analysed the clinical data to evaluate the effectiveness of this service. Patients with NAFLD (n=165) who had attended two or more appointments were included. Prespecified clinical data were collected prospectively at clinic appointments and analysed retrospectively. Interventions offered included lifestyle advice, signposting to weight loss services and pharmacological treatment of diabetes and cardiovascular risk factors. Median follow-up was 13 months (range: 2-34). 59% (n=97) of patients had type 2 diabetes mellitus (T2DM). 53% (n=87) underwent liver biopsy of whom 18% (n=16) had cirrhosis. Median alanine aminotransferase (ALT) reduced by 11 IU/L (p<0.0001), median weight reduced by 3.3 kg (p=0.0005). There were significant reductions in HbA1c, total cholesterol and liver stiffness. Specifically, in patients with T2DM, HbA1c decreased by 4 mmol/mol (p=0.01) with significant reductions in ALT, weight and total cholesterol. Relative cardiovascular risk assessed by the QRISK3 score reduced in the whole cohort and in those with T2DM. Health economic modelling suggested the clinic intervention among those patients with poorly controlled T2DM was cost-effective. In conclusion, a multidisciplinary approach to the management of patients with NAFLD in this observational cohort study was associated with improvements in liver-related and cardio-metabolic related health parameters and with evidence of cost-effectiveness in patients with poorly controlled T2DM. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetes mellitus; economic evaluation; fatty liver; non-alcoholic steatohepatitis

Year:  2019        PMID: 31682643      PMCID: PMC6788125          DOI: 10.1136/flgastro-2018-101155

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  33 in total

1.  Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; R Tessari; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2006-04       Impact factor: 4.359

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.

Authors:  Takamasa Ohki; Akihiro Isogawa; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

4.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

Review 6.  Effectiveness of Dietetic Consultations in Primary Health Care: A Systematic Review of Randomized Controlled Trials.

Authors:  Lana J Mitchell; Lauren E Ball; Lynda J Ross; Katelyn A Barnes; Lauren T Williams
Journal:  J Acad Nutr Diet       Date:  2017-08-19       Impact factor: 4.910

Review 7.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

8.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Authors:  Eduardo Vilar-Gomez; Yadina Martinez-Perez; Luis Calzadilla-Bertot; Ana Torres-Gonzalez; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Scott L Friedman; Moises Diago; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2015-04-10       Impact factor: 22.682

9.  Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.

Authors:  T Marjot; E Sbardella; A Moolla; J M Hazlehurst; G D Tan; M Ainsworth; J F L Cobbold; J W Tomlinson
Journal:  Diabet Med       Date:  2018-01       Impact factor: 4.359

10.  Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data.

Authors:  Idil Arsik; Jennifer K Frediani; Damon Frezza; Wen Chen; Turgay Ayer; Pinar Keskinocak; Ran Jin; Juna V Konomi; Sarah E Barlow; Stavra A Xanthakos; Joel E Lavine; Miriam B Vos
Journal:  Children (Basel)       Date:  2018-05-25
View more
  17 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

Review 2.  Advancing the global public health agenda for NAFLD: a consensus statement.

Authors:  Jeffrey V Lazarus; Henry E Mark; Quentin M Anstee; Juan Pablo Arab; Rachel L Batterham; Laurent Castera; Helena Cortez-Pinto; Javier Crespo; Kenneth Cusi; M Ashworth Dirac; Sven Francque; Jacob George; Hannes Hagström; Terry T-K Huang; Mona H Ismail; Achim Kautz; Shiv Kumar Sarin; Rohit Loomba; Veronica Miller; Philip N Newsome; Michael Ninburg; Ponsiano Ocama; Vlad Ratziu; Mary Rinella; Diana Romero; Manuel Romero-Gómez; Jörn M Schattenberg; Emmanuel A Tsochatzis; Luca Valenti; Vincent Wai-Sun Wong; Yusuf Yilmaz; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-27       Impact factor: 46.802

3.  What's new in non-alcoholic fatty liver disease?

Authors:  Jessica Spiers; James Hallimond Brindley; Wenhao Li; William Alazawi
Journal:  Frontline Gastroenterol       Date:  2022-05-31

Review 4.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24

Review 5.  Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?

Authors:  Kiarash Riazi; Maitreyi Raman; Lorian Taylor; Mark G Swain; Abdel Aziz Shaheen
Journal:  Nutrients       Date:  2019-11-26       Impact factor: 5.717

6.  Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes.

Authors:  Binayak Sinha; Debasis Datta; Samit Ghosal
Journal:  JGH Open       Date:  2020-12-07

Review 7.  Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.

Authors:  Amedeo Lonardo; Juan Pablo Arab; Marco Arrese
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

8.  Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease.

Authors:  Laura Jane Neilson; Louise Macdougall; Phey Shen Lee; Timothy Hardy; David Beaton; Subashini Chandrapalan; Alaa Ebraheem; Mohammed Hussien; Sarah Galbraith; Shi Looi; Sophia Oxenburgh; Naw April Phaw; William Taylor; Laura Haigh; Kate Hallsworth; Dina Mansour; Jessica K Dyson; Steven Masson; Quentin Anstee; Stuart McPherson
Journal:  Frontline Gastroenterol       Date:  2021-01-04

Review 9.  Fighting liver fat.

Authors:  David Koeckerling; Jeremy W Tomlinson; Jeremy F Cobbold
Journal:  Endocr Connect       Date:  2020-07       Impact factor: 3.335

10.  Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review.

Authors:  Siôn A Parry; Leanne Hodson
Journal:  Adv Ther       Date:  2020-03-07       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.